Product Code: RP-ID-10151864 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10151864
Market Overview:
Global Cell Therapy Technologies Industry Market Research 2022-2030
"The global cell therapy technology market is expected to grow at a compound annual growth rate of approximately ~17% from 2022 to 2030, and is expected to reach a market value of approximately ~USD 10 billion by 2030. Cells used for cell therapy are classified according to their ability to transform into different types of cells. In May 2019, AveXis, a Novartis company, announced that the U.S. Food and Drug Administration (FDA) approved Zolgensma (onasemnogene abeparvovec-xioi) for the treatment of pediatric patients with spinal muscular atrophy (SMA) under 2 years of age.
In addition, in July 2020, the US Food and Drug Administration (USFDA) approved Tecartus (brexucabtagene autoleucel), a cell-based therapy for the treatment of adult patients diagnosed with mantle cell lymphoma (MCL). The patient does not respond to other types of treatment or has fallen. Tecartus, is a chimeric antigen receptor (CAR). T cell therapy is the first cell-based therapy approved by the FDA for the treatment of MCL.
Market drivers and trends:
Strong call for stem cell therapy :
According to the Australian Government’s Ministry of Health, stem cell therapy is an effective treatment for blood diseases, such as leukemia, Hodgkin’s disease and other non-Hodgkin’s diseases. Lymphoma. Stem cells have the ability to treat many other types of incurable diseases. The self-feeding process of stem cells is a new way to regenerate drugs.
In July 2020, the University of Pennsylvania Medical Department in Philadelphia commented that the self-feeding process of embryonic stem cells is called chaperone-mediated autophagy (CMA) and its related metabolites, which can be used as a promising way to repair or regenerate damaged cells and organs. New therapeutic target. The new preclinical studies in the first phase show that stem cells maintain chaperone-mediated autophagy (CMA) at a low level and promote self-renewal. When stem cells mature or are ready, it shuts down inhibition to improve CMA, etc. Activity and differentiation. In specialized cells. The recent discovery of the role of autophagy in stem cells is the beginning of new research that has enhanced the ability of researchers and doctors and scientists to introduce better therapies and treat various diseases.
Are stem cells the solution to the COVID-19 pandemic?
Stem cells may be the best solution to fight the COVID-19 pandemic. Currently, 17 clinical trials are evaluating the therapeutic potential of mesenchymal stem cells (MSC) for the treatment of COVID-19; most of them are intravenously administered through clinical trials to test MSC-derived exosomes through inhalation. MSCs may be a promising treatment for COVID-19 infection.
Since the key to the treatment of COVID-19 lies in the management of cytokine storms in the lungs, considering that the mechanism of action (MOA) is through related immunomodulatory and anti-inflammatory properties, MSCs can be used as suitable modulators. Research on other types of stem cells used to treat COVID-19 infection involves genetically engineered human-induced pluripotent stem cells. Regardless of the urgency of the need for MSC-based therapy for COVID-19, the production of MSC must comply with Good Manufacturing Practices (GMP) and regulations before it can be approved for use in humans.
Segmentation perspective:
The cell therapy technology market is based on products, cell types, processes, and end users. By product, the cell therapy technology market is divided into consumables, equipment and systems, and software. Depending on the cell type, it is secreted into T cells, stem cells, and other cells. The process cell therapy technology market is segmented into cell processing, cell preservation, distribution and handling, process monitoring and quality control. End users are further divided into biopharmaceutical and biotechnology companies and contract research organizations (CRO) as well as research institutions and cell banks.
Consumables are expected to have the largest market share in the cell therapy technology market:
The consumables segment used to occupy the largest market share, and the same trend is expected to continue in the next few years. Factors contributing to the growth of this market segment include increased investment in advanced product development and high government involvement to improve research based on cells that have fully contributed to growth. The Cell and Gene Therapy (CGT) platform promotes science/new platforms to strategically accelerate all activities in the value chain by breaking down innovative treatments for patients. In December 2020, Bayer announced the launch of a new cell and gene therapy (CGT) platform in its pharmaceutical division.
Strategically, Bayer focuses on selected areas of C&G, such as stem cell therapy (focusing on induced pluripotent cells or iPSC), gene enhancement, gene editing, and allogeneic cell therapy for different indications. In November 2020, the Canadian government and JDRF announced new research funding to accelerate stem cell-based type 1 diabetes therapies. In Canada, more than 300,000 Canadians suffer from type 1 diabetes (T1D), an autoimmune disease that causes dysfunction, damage or loss of pancreatic beta cells that produce insulin in the body. The Minister of Health announced an investment of US$6 million through the CIHR-JDRF alliance to defeat diabetes.
Cell processing is growing rapidly:
The cell processing segment has dominated in the past and will have a positive impact in the coming years. This segment will record the highest compound annual growth rate during the analysis period. One of the important factors that promote the growth of the cell processing field is the use of high-efficiency cell therapy culture media and equipment in cell processing, especially in culture media processing technology. This has played a positive role in achieving the highest growth in this segment in the world market.
According to the registration information released by the Regenerative Medicine Alliance in mid-2020, there are 675 ongoing cell therapy and cell-based immuno-oncology clinical trials worldwide, but few commercially available cell therapies are still under development. In the cell processing process, there are several factors that need to be considered, such as safety and efficiency, transfer to the manufacturing process, lack of scalability, high cost of facilities, labor, and equipment, and the complexity associated with the process involved.
To avoid this situation, manufacturers are focusing on developing new technologies to solve these types of problems. For example, in October 2020, Thermo Fisher Scientific announced the launch of a closed system for manufacturing cell therapies. Thermo Fisher Scientific has launched the Gibco CTS Rotea countercurrent centrifuge system, which is a modular closed cell therapy treatment system that can be used as a solution to this problem. The device is scalable, cost-effective, and can develop and manufacture cell therapies. This device is specifically designed to facilitate the workflow from research to clinical development and good manufacturing practice (GMP) commercial production.
Regional overview:
North America has the largest market share in the global cell therapy technology market. In the past, North America had a more commendable share of the cell therapy technology market.
This can be attributed to the increase in the prevalence of chronic diseases, the increase in health care expenditures, the increase in disposable income, the increase in health care awareness, and the availability of technologically advanced equipment in the North American market. Inc., STEMCELL Technologies Inc., Thermo Fisher Scientific, Beckman Coulter, Lonza Group AG, Miltenyi Biotec, Merck KGaA, GE Healthcare, etc. End-user process monitoring and quality control market Biopharmaceutical and biotech companies as well as CRO research institutes and cell banks. "
Related Reports
Proof of Quality & Reliability
